Product Code: 596200419
Pipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But where will new therapies fit into the UC treatment paradigm? How will they affect existing brands? And what will it all mean for patients?
Get the answers in FirstWord's KOL Insight: Ulcerative Colitis report. This 104 page report gives you an in-depth account of how 12 key opinion leaders (KOLs) in the US and Europe see the UC landscape.
Get KOLs' candid thoughts about how the UC treatment paradigm is changing, where pipeline drugs are likely to be positioned, and which clinical trials will have the greatest impact on important treatment decisions.
The report also includes analyses of 5 currently marketed UC drugs , and 7 pipeline drugs currently in clinical trials.
View: North American KOLs, EU KOLs, mild-to-moderate UC drugs , moderate-to-severe UC drugs
Plus: Order the report today and you'll also receive three quarterly FirstWord Therapy Trends Update Bulletins absolutely free!
Answering Key Questions
Get answers to key questions about marketed and pipeline ulcerative colitis therapies:
- Uceris, Cortiment: How are doctors using Uceris? What factors are affecting its uptake?
- LT 02: Where in the early-to-moderate UC treatment paradigm do KOLs see LT02?
- Anti-TNFs Inhibitors (Remicade, Humira, Simponi) : How will biosimilars in the pipeline affect branded versions of these drugs?
- Entyvio: Can first-to-market advantage help Entyvio stave off competition?
- Etrolizumab: How will this pipeline integrin inhibitor be positioned?
- AJM 300: Do KOLs expect orally administered integrin antagonists such as AJM 300 to be effective treatments?
- Tofacitinib: Do KOLs have the information they need to position tofacitinib in the treatment paradigm?
- Ozanimod: Which brands will compete with this oral pipeline therapy?
- Kappaproct: How do KOLs view Kappaproct's potential to treat moderate-to-severe-UC?
- Alicaforsen: For which patient population are doctors most likely to use alicaforsen?
- The future of 5-ASAs: Find out whether 5-ASAs will remain the go-to treatment for mild-to-moderate UC
- New mild-to-moderate UC treatments: Learn how pipeline drugs for mild-to-moderate UC will affect first-line treatment
- Uceris in the treatment paradigm: Understand how doctors use Uceris, and find out whether they're likely to expand its use in the future
- Changes to integrin inhibitor use: Is the way doctors use Entyvio changing? See what that could mean for the UC treatment paradigm
- Effect of new integrin inhibitors: Explore the impact of new integrin inhibitors-and other pipeline drugs-on Entyvio
- Biosimilars in the anti-TNF market: Use of anti-TNFs is on the rise. Discover how biosimilars currently in the pipeline will affect the market
- Oral therapies: Find out how new oral therapies will affect moderate-to-severe UC treatment
Key issues explorede
- Mild-to-moderate UC landscape: Will cheap, safe, and effective 5-ASAs continue to be the mainstay treatment? Which pipeline products will also be used for mild-to-moderate UC?
- Moderate-to-severe UC landscape: How do KOLs expect the treatment paradigm to change as later-line therapies in the pipeline come to market?
- Important clinical trials: Key clinical trials will affect important treatment decisions. Which trials are most important? Which brands are most affected?
- Impact of biosimilars: As anti-TNF biosimilars come to market, how are branded drug makers likely to respond? What do KOLs think will drive biosimilar adoption?
- Changing use of Entyvio: How is the way doctors use Entyvio likely to change? What role will pipeline products play?
- Oral therapies on the way: KOLs think oral therapies will have a significant impact on UC treatment. How will they be positioned in the treatment paradigm, and why?
- Potential of earlier-stage products: How do KOLs view the prospects of early-stage drugs such as Apremilast, Bertilimumab, and Mongersen?
A report based on expert knowledge
KOLs from North America
- Prof Jean-Frédéric Colombel, MD. Professor of Medicine and Director of the Susan and Leonor Feinstein IBD Center, Icahn School of Medicine, New York, USA.
- Dr Brian Behm, MD. Associate Professor of Medicine and Director of the Inflammatory Bowel Disease Program, University of Virginia, Virginia, USA.
- Prof David Sachar, MD. Clinical Professor of Medicine and Director Emeritus of the GI Division, Mount Sinai School of Medicine, New York, USA.
- Dr Joseph Feuerstein, MD. Gastroenterologist (Board Certified), Beth Israel Deaconess Medical Centre, Boston, USA.
- Dr Suneeta Krishnareddy, MD. Gastroenterologist (Board Certified), faculty of Digestive and Liver Diseases, Columbia University Medical Center, New York, USA.
- Prof Burton Korelitz, MD. Director for Clinical Research in Inflammatory Bowel Diseases, Lenox Hill Hospital, New York, USA.
KOLs from Europe
- Dr SS Hoque. Consultant Physician and Gastroenterologist, Barts Health NHS Trust at Whipps Cross University Hospital, London, UK.
- Dr Renato Caviglia, MD, Ph.D. Consultant, Department of Gastroenterology and Digestive Endoscopy, Ospedale Israelitico, Roma, Italy.
- Dr Thierry Paupard. Head of the Gastroenterology, Centre Hospitalier de Dunkerque, Dunkerque, France.
- German KOL. Expert in Crohn's disease and ulcerative colitis, Germany.
- German KOL. Chief and head of gastroenterology, hospital, Germany.
- Dr Marcus Harbord. Consultant Physician and Gastroenterologist, Chelsea & Westminster Hospital, London, UK
Get KOL insights into
Therapies for Mild-to-moderate Ulcerative Colitis
- Uceris, Cortiment (Budesonide MMX; Cosmo/Santarus/Ferring)
- LT 02 (phosphatidylcholine controlled-release; Lipid Therapeutics/Dr Falk Pharma/Nestlé Health Science)
Therapies for Moderate-to-Severe Ulcerative Colitis
- Branded Anti-TNFs:
- Remicade (Infliximab; Janssen Biotech/Merck & Co. /Mitsubishi Tanabe)
- Humira (Adalimumab; AbbVie/Eisai)
- Simponi (Golimumab; Janssen Biotech/Merck & Co.)
- Anti-TNF Biosimilars
- Remsima (Infliximab; Celltrion)
- Inflectra (Infliximab; Hospira)
- Entyvio (Vedolizumab; Millennium/Takeda.)
- Etrolizumab (RG 7413, rhuMab beta7; Roche)
- AJM 300 (Ajinomoto/Kissei)
- Tofacitinib (CP 690550; Pfizer)
- Ozanimod (RPC 1063; Celgene)
- Kappaproct (cobitolimod, DIMS 0150; InDex Pharmaceuticals)
- Alicaforsen (ISIS 2302; Atlantic Healthcare/Isis Pharmaceuticals)
Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
- Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, December 2015.
- You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.